Psittacosis future or investigational therapies
|
Psittacosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psittacosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Psittacosis future or investigational therapies |
|
Risk calculators and risk factors for Psittacosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Future
- Future challenges lay in the rigorous reporting of infections in both poultry and poultry workers and in the development of an avian and human vaccine.[1]
- Use of ovotransferrin as anitmicrobial in poultry to reduce dissemination of bacteria into air. [2]
References
- ↑ Deschuyffeleer TP, Tyberghien LF, Dickx VL; et al. (2012). "Risk assessment and management of Chlamydia psittaci in poultry processing plants". Ann Occup Hyg. 56 (3): 340–9. doi:10.1093/annhyg/mer102. PMID 22302240. Unknown parameter
|month=ignored (help) - ↑ Van Droogenbroeck C, Dossche L, Wauman T; et al. (2011). "Use of ovotransferrin as an antimicrobial in turkeys naturally infected with Chlamydia psittaci, avian metapneumovirus and Ornithobacterium rhinotracheale". Vet. Microbiol. 153 (3–4): 257–63. doi:10.1016/j.vetmic.2011.05.016. PMID 21885218. Unknown parameter
|month=ignored (help)